Last reviewed · How we verify
Bupropion Augmentation
Bupropion Augmentation, marketed by the Centre for Addiction and Mental Health, is an established treatment in the psychiatric market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market position. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Bupropion Augmentation |
|---|---|
| Also known as | Wellbutrin |
| Sponsor | Centre for Addiction and Mental Health |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE) (PHASE4)
- Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (PHASE2)
- Predictors of Cognitive Outcomes in Geriatric Depression (PHASE4)
- RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT) (PHASE4)
- Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (PHASE4)
- Psychoeducational Group for Depression (NA)
- Multimodal Cue Exposure Therapy for Smoking Cessation (PHASE2)
- A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupropion Augmentation CI brief — competitive landscape report
- Bupropion Augmentation updates RSS · CI watch RSS
- Centre for Addiction and Mental Health portfolio CI